MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...

MSD Global Health Innovation Fund, a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, who became an Evaxion shareholder in December 2023, participated in this offering along with ...

TD Cowen, William Blair and Lake Street Capital Markets are the bookrunners for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as ...

Mortgage REIT Sunrise Realty Trust (SUNS) announced on Tuesday the pricing of an upsized underwritten public offering of 5.75M shares of common stock at $12.00 per share for gross proceeds of ~$69M.

BERWYN, Pa. - Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX), a company engaged in developing drug delivery systems for pain management, announced the pricing of its public offering at $0.20 per share of ...

Atlas Energy Solutions Inc. (NYSE: AESI) (“Atlas” or the “Company”) today announced the pricing of an upsized underwritten public offering (the “Offer ...

Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...

By raising ₹500-600 crore, this firm aims to strengthen its market position and adapt to evolving global trends.

In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

Investing.com -- Immunome, Inc. (NASDAQ:IMNM) shares fell sharply by 9.6% following the announcement of the pricing of its upsized public offering of common stock. The biotechnology company ...